John Parkinson

The authorization was given to Invivyd’s pemivibart (Pemgarda), and it is indicated for adults and adolescents with moderate-to-severe immune compromised conditions.

This week learn more about CDC's strategies to reduce waterborne diseases; the US change to a trivalent influenza vaccine; new data for Merck's pneumococcal vaccine; and how PCR testing can influence a patient diagnosis and outcome.

A large European study looked at a modern-day communication method and its influence on a public health initiative to increase immunizations.

The company’s investigational vaccine, V116, is a conjugate vaccine and demonstrated immunogenicity for all 21 serotypes across the studied adult groups.

Today serves as a reminder to everyone that there are still no diagnostic tests or FDA-approved treatments for the post-viral condition.

The antifungal’s designation ensures its market viability and gives the youngest pediatric patients a therapy for health conditions that have been associated with high mortality rates.

A new study shows how correcting misinformation in a certain way can change patients’ attitudes towards vaccination.

An experienced measles clinician offers insights on the increase of incidence rates, preventative measures, and how vitamin A treatment can help those with the disease.

State health officials did not disclose the origin of transmission.

The first-in-class entry inhibitor delivered therapeutic benefits over a long study period for patients with chronic infection.

A team developed and validated a new analytic method to quantify omadacycline and its epimerization in stool to facilitate microbiome research.

The therapy, lenacapavir, showed sustained virological suppression and safety over a 2-year period in this treatment-challenged patient population.

Both the use of a vaginal ring or oral pre-exposure prophylaxis were found to be safe for HIV prevention throughout pregnancy.

Biomarkers associated with mortality differed by sex and there may be distinct pathophysiologic mechanisms that account for the increased risk seen in females, according to investigators.

A reduced risk of individual symptoms associated with the condition was reported when patients were administered the therapy within 2 days of admittance.

A National Institutes of Health (NIH) sponsored study reveals a need for more accurate screening in Black people and cisgender women.

In a phase 1 study, the investigational therapy known as cabotegravir ultra long-acting (CAB-ULA), showed positive pharmacokinetic, tolerability, and safety data supporting a prospective move to the next stage of clinical development.

A new study offers some clues into the pathophysiology and biomarkers of post-acute Sequelae of SARS-CoV-2 (PASC).

From the ongoing CROI meeting, the FDA approved antiretroviral was studied over a 2-year period and showed treatment benefit.

Reduced childhood immunizations because of personal beliefs and fears, and the quarantine's effect, along with a lack of knowledge about transmissibility and the seriousness of measles are causing unnecessary suffering and danger to people, especially in children.

With today's vote, the federal agency’s Advisory Committee on Immunization Practices (ACIP) is now recommending people 65 years of age and older get 1 more dose of the 2023-2024 formula of the COVID-19 vaccine.

A new paper outlines how these variables can be connected to create situations where patients get less-than-optimal outcomes.

The new indication for bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF (Biktarvy) is for patients with suppressed viral loads, pre-existing resistance.

Shionogi’s investigational therapy, ensitrelvir, demonstrated a median time-to-symptom resolution of approximately 1 day shorter in the antiviral group versus placebo.

The federal agency did not request further trials for the investigational therapy, cefepime-taniborbactam, but wanted more information about its chemistry, manufacturing, and controls.

It affects a limited number of Dole-branded and private label salad kits, and no cases of illness associated with the Dole recall have been reported.

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

The outbreak has seen 2 deaths and 23 hospitalizations across 11 states.

Phase 2 study for the investigational antiviral, ZSP1273 (onradivir), demonstrated safety and efficacy in reducing the time to resolution of symptoms in a multicenter trial.